Our team operates from a deep scientific and technical understanding of your device, drug, or diagnostic test. We have worked at/with the largest diagnostic and pharma companies and understand the need for selecting the best partner to insure an aligned strategy between drug and diagnostic. We are experts at developing cross asset/diagnostic strategies to enhance the seamless adoption of therapies to guide precision medicine.
We are engaged by large investment firms and venture capital for our expertise on new medical devices, clinical assays, and technologies.
We have expertise working with early stage companies to develop go-to-market strategies.
Typical engagements focus in the early lifecycle on helping clients to define the potential of their asset in the context of future standards of care, prioritize the best targets and define market opportunity and competitive intensity, in the pre-launch window, we’re supporting all aspects of go-to-market and launch strategies and subsequently work closely with clients to execute analytical work streams to optimize the impact of commercial programs and tactics.